Related Experiment Video
Updated: Jun 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
New targets in antiretroviral therapy 2006
Aimee Wilkin1, Judith Feinberg
1Department of Medicine, Section of Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Purpose Of Review:
Novel antiretroviral therapies that utilize new viral and cellular targets are needed to increase the range of treatment options for individuals living with HIV. Several novel therapies are now proceeding through clinical trials, and clinical and safety information is starting to accumulate.
Recent Findings:
The review outlines progress to date and important considerations for the drugs that are furthest along in clinical development from the following new classes of anti-HIV therapy: co-receptor inhibitors (maraviroc, vicriviroc and AMD-070), integrase inhibitors (MK-0518 and GS-9137), maturation inhibitors (PA-457), and entry inhibitors (TNX-355). The focus is on novel drugs for which initial data are available from studies in both healthy volunteers and studies involving HIV-infected participants.
Summary:
Although the drugs reviewed may potentially provide important new options for existing antiretroviral treatment regimens, much information regarding the safety, efficacy and positioning of the drugs remains to be determined. As further clinical trial information accumulates, it will be important for HIV clinicians to monitor the progress of these novel therapies.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Retroviruses
Inhibitors of Viral Protein Synthesis
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

